Thermo Fisher Scientific (TMO) Tops Q3 EPS by 2c; Tightens Guidance

Thermo Fisher Scientific (NYSE: TMO) reported Q3 EPS of $1.71, $0.02 better than the analyst estimate of $1.69. Revenue for the quarter came in at $4.17 billion versus the consensus estimate of $4.21 billion.

Thermo Fisher Scientific sees FY2014 EPS of $6.87-$6.95, versus prior guidance of $6.85-$6.97 and the consensus of $6.92. Thermo Fisher Scientific sees FY2014 revenue of $16.74-16.82 billion, versus prior guidance of $16.86-16.98 billion and the consensus of $16.89 billion.

“We’re pleased to extend our long track record of consistently delivering strong adjusted EPS growth,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “We leveraged our solid top-line results and our culture of operational discipline to achieve excellent performance on the bottom line. I’m also pleased to report that the Life Technologies integration is going very well, and it was another great quarter for innovation across our technology platforms.

“We launched a number of new products during the quarter to strengthen our leadership position in the key markets we serve. Among the highlights was our new Vanquish UHPLC system and columns, a potential game-changer for customers in applied markets who need to analyze high volumes of samples. At AACC, we showcased our expanded offering for customers in clinical laboratories, including allergy and autoimmunity tests, a range of immunosuppressant assays and, especially notable, the new Prelude MD HPLC, Endura MD mass spectrometer and ClinQuan MD software for clinical use. We’re also successfully executing our strategy to expand the markets for our next-generation sequencing technologies with the launch of our Ion PGM Dx system and reagents for clinical use in the U.S. and Europe.”

For earnings history and earnings-related data on Thermo Fisher Scientific (TMO) click here.

You May Also Be Interested In

• Equifax (EFX) shares tumble as Q2, full-year guidance falls short
• Crown Castle (CCI) Tops Q1 EPS by 1c; maintains outlook for FY24
• Logansport Financial Corp. (LOGN) Reports Q1 EPS of $0.44